Type 2 Diabetes

Type 2 diabetes is a chronic condition in which the body cannot use insulin effectively (a state called insulin resistance) and, over time, the pancreas cannot make enough insulin to overcome it. The result is blood sugar (glucose) that runs too high, year after year, slowly damaging blood vessels and nerves throughout the body. It is by far the most common form of diabetes — accounting for roughly 90–95% of all cases — and it has become one of the defining chronic diseases of the modern world. In the United States alone, an estimated 38 million people (about 1 in 9 adults) have diabetes, and another 98 million have prediabetes, a warning stage that usually goes unnoticed. The encouraging news, backed by large clinical trials, is that type 2 diabetes is largely preventable, highly treatable, and — caught early and met with enough weight loss — sometimes even reversible into remission.

What Is Type 2 Diabetes?
How It Differs From Type 1 and Prediabetes
Symptoms
Causes & Risk Factors
Diagnosis
Blood Sugar Targets & Monitoring
Treatment
Diet, Lifestyle & Natural Support
Preventing & Reversing Type 2 Diabetes
Complications
Prevention
Key Research Papers
Connections

What Is Type 2 Diabetes?

To understand type 2 diabetes, it helps to understand what insulin does. Every time you eat, carbohydrates are broken down into glucose, which enters the bloodstream. In response, the pancreas releases insulin — a hormone that acts like a key, unlocking cells so glucose can move out of the blood and into muscle, fat, and liver cells to be used for energy or stored for later. Insulin keeps blood glucose in a narrow, safe range.

In type 2 diabetes, two things go wrong at once. First, cells become resistant to insulin's signal — the key still fits, but the lock is stiff, so the pancreas has to produce more and more insulin to get the same effect. For years, an over-worked pancreas can keep up, and blood sugar stays near normal (this is the "compensated" phase, often overlapping with prediabetes). Second, over time the insulin-producing beta cells of the pancreas wear out and fall behind. When insulin supply can no longer overcome insulin resistance, glucose backs up in the bloodstream and diabetes appears. This is why type 2 diabetes is described as a combination of insulin resistance plus a relative (not absolute) insulin deficiency.

Excess fat — especially visceral fat packed around the liver and pancreas — is a central driver of insulin resistance. This is also why type 2 diabetes travels in a cluster with obesity, high blood pressure, and abnormal cholesterol known as metabolic syndrome, and why the underlying problem is often called insulin resistance.

How It Differs From Type 1 and Prediabetes

All forms of diabetes share high blood sugar, but the causes are very different — and the distinction changes treatment completely.

Type 1 diabetes is an autoimmune disease: the immune system destroys the pancreas's beta cells, so the body makes little or no insulin at all. It is an absolute insulin deficiency, usually appears in childhood or young adulthood, is not caused by lifestyle, and requires insulin from diagnosis to survive. It accounts for roughly 5–10% of diabetes.
Type 2 diabetes is primarily a disease of insulin resistance with a gradually failing insulin supply. It develops over years, is strongly linked to weight, activity, genetics, and age, and can often be managed at first with lifestyle and pills before insulin is ever needed.
Prediabetes is the in-between zone: blood sugar is higher than normal but not yet high enough to diagnose diabetes (A1c 5.7–6.4%, or fasting glucose 100–125 mg/dL). It is a loud warning sign — without changes, many people with prediabetes progress to type 2 diabetes within a few years — but it is also the stage where prevention works best.

A few less-common forms blur the lines. LADA (latent autoimmune diabetes in adults) is a slow-onset autoimmune diabetes that can be mistaken for type 2. Gestational diabetes appears in pregnancy and raises a woman's lifetime risk of type 2 diabetes. If the picture is unusual — a lean person, rapid weight loss, or ketones — clinicians test antibodies to be sure the diagnosis is correct.

Symptoms

Type 2 diabetes is notorious for being silent. Because blood sugar rises slowly, many people have no obvious symptoms for years and are diagnosed only through a routine blood test — often after the disease has already begun affecting the body. When symptoms do appear, the classic ones come from glucose spilling into the urine and pulling water with it:

Frequent urination (polyuria), especially at night
Excessive thirst (polydipsia)
Increased hunger (polyphagia), sometimes with unexplained weight loss
Fatigue and low energy
Blurred vision as fluid shifts change the shape of the lens
Slow-healing cuts and sores, and frequent infections (skin, gum, urinary, yeast)
Tingling or numbness in the hands or feet — an early sign of nerve damage
Darkened, velvety skin in folds of the neck or armpits (acanthosis nigricans), a visible marker of insulin resistance

Because the early phase is so quiet, the absence of symptoms is not reassurance — screening is what catches type 2 diabetes in time to prevent complications.

Causes & Risk Factors

Type 2 diabetes arises from a mix of genetics and environment. You cannot change some risk factors, but the most powerful ones are modifiable.

Risk factors you cannot change:

Family history — a parent or sibling with type 2 diabetes strongly raises risk (the genetic contribution is larger than in type 1).
Age 45 and older, though it is increasingly diagnosed in younger adults and even children.
Ethnicity — higher rates in people of African American, Hispanic/Latino, Native American, Asian American, and Pacific Islander descent.
History of gestational diabetes or delivering a baby over 9 pounds.
Polycystic ovary syndrome (PCOS), which is closely tied to insulin resistance.

Risk factors you can influence:

Overweight and obesity, particularly excess abdominal (visceral) fat — the single largest modifiable driver.
Physical inactivity — muscle is the body's biggest glucose "sink," and inactive muscle handles glucose poorly.
Diets high in refined carbohydrates, sugary drinks, and ultra-processed foods.
High blood pressure and abnormal cholesterol (low HDL, high triglycerides).
Smoking and obstructive sleep apnea, both independently linked to insulin resistance.

These cluster together because they share a common root in insulin resistance — which is why addressing weight, activity, and diet improves several of them at once.

Diagnosis

Type 2 diabetes is diagnosed with simple, widely available blood tests. Any one of the following meets the threshold; in the absence of clear symptoms, an abnormal result should be confirmed with a repeat test on a different day.

Test	Normal	Prediabetes	Diabetes
Hemoglobin A1c (3-month average glucose)	Below 5.7%	5.7–6.4%	6.5% or higher
Fasting plasma glucose (no food 8+ hours)	Below 100 mg/dL	100–125 mg/dL	126 mg/dL or higher
Oral glucose tolerance test (2-hour, after 75 g glucose drink)	Below 140 mg/dL	140–199 mg/dL	200 mg/dL or higher
Random glucose (with classic symptoms)	—	—	200 mg/dL or higher

The A1c is the most convenient test because it reflects average blood sugar over the previous 2–3 months and does not require fasting. (In millimoles, 126 mg/dL equals 7.0 mmol/L and 200 mg/dL equals 11.1 mmol/L.) A1c can be misleading in some situations — anemia, recent blood loss, pregnancy, or certain hemoglobin variants — where a fasting glucose or glucose tolerance test is preferred. Once diabetes is diagnosed, clinicians often check a fasting insulin level and a lipid panel to gauge insulin resistance and cardiovascular risk.

Blood Sugar Targets & Monitoring

The goal of treatment is not simply a lower number — it is fewer complications with the fewest side effects, tailored to the individual. The American Diabetes Association's general targets for most non-pregnant adults are:

A1c below 7% for most adults — but individualized. A tighter goal (around 6.5%) may suit younger, healthier people early in the disease, while a looser goal (up to 8%) is safer for older or frail patients, those with a history of severe low blood sugar, or limited life expectancy.
Fasting and pre-meal glucose of 80–130 mg/dL.
Peak glucose after meals below 180 mg/dL (measured 1–2 hours after eating).

Chasing very low A1c targets aggressively is not always better: the large ACCORD trial found that pushing A1c below 6% with intensive drug therapy actually increased deaths in high-risk patients, a landmark reminder that the target must fit the person. Monitoring is done with fingerstick meters or, increasingly, with continuous glucose monitors (CGMs) — small sensors worn on the arm that read glucose every few minutes. CGMs add a modern metric, time in range: aiming to keep glucose between 70 and 180 mg/dL for at least 70% of the day, while minimizing time spent low.

Treatment

Treatment for type 2 diabetes has been transformed over the past decade. The old approach was "lower the sugar with whatever works." The modern approach is organ-protective: choose medications not only for their glucose-lowering power but for their proven ability to protect the heart and kidneys and support weight loss.

Foundation — lifestyle. Weight loss, nutrition, and physical activity are the base of every treatment plan at every stage, not an alternative to medication (see the next section).

First-line medication — metformin. Metformin lowers glucose mainly by reducing the liver's glucose output and improving insulin sensitivity. It is inexpensive, does not cause weight gain or (by itself) low blood sugar, and has a decades-long safety record. In the landmark UKPDS 34 trial, metformin reduced diabetes-related complications and death in overweight patients, cementing it as the standard starting drug.

Organ-protective agents — often added early or even first, based on the patient:

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) make the kidneys excrete excess glucose in the urine. Beyond glucose control, they protect the heart and kidneys: EMPA-REG OUTCOME showed empagliflozin cut cardiovascular death, and CREDENCE showed canagliflozin slowed the progression of diabetic kidney disease. They are now first-choice add-ons for anyone with heart failure, kidney disease, or established cardiovascular disease.
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) mimic a gut hormone that boosts insulin after meals, slows stomach emptying, and reduces appetite — producing substantial weight loss along with glucose control. In the LEADER trial, liraglutide reduced cardiovascular events and death. Newer dual GIP/GLP-1 agonists such as tirzepatide produce even greater weight loss.
Other pills: DPP-4 inhibitors (sitagliptin) are weight-neutral and gentle; sulfonylureas (glipizide, glimepiride) are cheap and effective but can cause low blood sugar and weight gain; pioglitazone improves insulin sensitivity.

Insulin is added when the pancreas can no longer keep up despite other therapies, or when blood sugar is very high at diagnosis. Needing insulin is a sign of the natural progression of the disease, not a personal failure. The overarching modern principle, reflected in the ADA's annually updated Standards of Care, is to match the drug to the whole person — heart, kidneys, weight, cost, and risk of low blood sugar — rather than treating the glucose number in isolation.

Diet, Lifestyle & Natural Support

Lifestyle change is the most powerful single intervention in type 2 diabetes — strong enough, in some cases, to push the disease into remission. It is genuine medicine, not a footnote.

Weight loss. Losing 5–10% of body weight meaningfully improves blood sugar; losing 10–15% can, in some people, reverse the disease (see below).
Eating pattern. No single "diabetic diet" wins for everyone, but the best-supported patterns share features: plenty of non-starchy vegetables, whole grains over refined, legumes, nuts, and lean protein; minimal sugary drinks and ultra-processed food. The Mediterranean diet has the strongest evidence for reducing cardiovascular risk, and lower-carbohydrate approaches can markedly improve A1c. Fiber slows glucose absorption and improves control.
Physical activity. Aim for at least 150 minutes per week of moderate activity plus resistance training twice weekly. Exercise lets muscles absorb glucose without needing much insulin — a direct workaround for insulin resistance — and even a short walk after meals blunts the post-meal spike.

Natural supplements — honest adjuncts, not replacements. Some supplements have real but modest evidence and should complement, never replace, proven therapy. Always tell your clinician what you take, as several interact with diabetes drugs:

Berberine has the strongest data of the group; small trials suggest glucose-lowering roughly comparable to metformin, though studies are limited in size and quality, and it can interact with many medications.
Cinnamon shows small, inconsistent effects on fasting glucose — a reasonable culinary addition, not a treatment.
Magnesium deficiency is common in type 2 diabetes and correcting a true deficiency may modestly improve insulin sensitivity.
Chromium is widely marketed for blood sugar, but the evidence is weak and inconsistent.

The bottom line: food, movement, and weight are the heavy lifters; supplements are, at best, small helpers around the edges.

Preventing & Reversing Type 2 Diabetes

For decades type 2 diabetes was considered a one-way street. That belief has changed. The landmark DiRECT trial in the UK put newly diagnosed patients on an intensive, medically supervised weight-management program (a low-calorie formula diet followed by structured food reintroduction). At one year, 46% achieved remission — normal blood sugar with no diabetes medication — and remission was tightly linked to how much weight people lost: about 86% of those who lost 15 kg or more went into remission. At two years, roughly a third remained in remission. Remission is generally defined as an A1c below 6.5% sustained for at least three months off glucose-lowering drugs.

Two lessons follow. First, early and substantial weight loss — roughly 15 kg / 33 lb — is the engine of remission, apparently by clearing fat out of the liver and pancreas so beta cells can recover. Second, remission is not the same as cure: weight regain brings diabetes back, so the change has to last. For people with obesity, bariatric (metabolic) surgery produces the highest and most durable remission rates of any intervention.

Prevention is just as striking. The U.S. Diabetes Prevention Program (DPP) enrolled people with prediabetes and found that a lifestyle program aiming for 7% weight loss and 150 minutes of weekly activity reduced progression to diabetes by 58% — substantially better than metformin, which reduced it by 31%. This is the evidence base behind the CDC's National Diabetes Prevention Program available across the U.S. today.

Complications

The reason type 2 diabetes matters so much is the long-term damage that persistently high glucose does to blood vessels — both the tiny ones (microvascular) and the large ones (macrovascular). Good control dramatically lowers this risk.

Microvascular (small-vessel) complications:

Diabetic retinopathy — damage to the retina's blood vessels and a leading cause of blindness in working-age adults. Regular dilated eye exams catch it early.
Diabetic kidney disease — the number-one cause of kidney failure worldwide. An annual urine albumin test detects it years before symptoms.
Peripheral neuropathy — nerve damage causing numbness, tingling, and pain in the feet, which combined with poor circulation can lead to foot ulcers and, in severe cases, amputation. Daily foot care is essential.

Macrovascular (large-vessel) complications:

Heart disease and stroke — the leading cause of death in type 2 diabetes; the condition roughly doubles cardiovascular risk.
High blood pressure and peripheral artery disease frequently accompany diabetes and compound the danger.
Non-alcoholic fatty liver disease is common and can progress to liver scarring.

Crucially, treating only blood sugar is not enough. The STENO-2 trial showed that a multifactorial approach — simultaneously controlling glucose, blood pressure, and cholesterol, plus aspirin where appropriate — roughly halved cardiovascular events and, in long-term follow-up, extended life. Modern SGLT2 inhibitors and GLP-1 agonists now build heart and kidney protection directly into diabetes therapy.

Prevention

Because type 2 diabetes usually develops slowly through a prediabetes stage, there is a real window to prevent it — and the tools are well proven:

Know your numbers. Adults should be screened starting at age 35 (earlier with risk factors) with an A1c or fasting glucose. Catching prediabetes is the whole opportunity.
Modest, sustained weight loss. Losing just 5–7% of body weight cuts the risk of progressing from prediabetes to diabetes by more than half.
Move regularly — 150 minutes of moderate activity per week, ideally with some strength training.
Eat a whole-food pattern rich in vegetables, legumes, whole grains, and healthy fats; cut sugary drinks and ultra-processed foods.
Don't smoke, prioritize sleep, and treat sleep apnea — each independently affects insulin sensitivity.
Consider metformin for the highest-risk individuals (for example, prediabetes with obesity or a history of gestational diabetes), as supported by the DPP.

Prevention is not about perfection — it is about small, durable changes that shift the odds decisively in your favor.

Key Research Papers

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352(9131):837-853.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998;352(9131):854-865.
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (Diabetes Prevention Program). New England Journal of Medicine. 2002;346(6):393-403.
Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet. 2018;391(10120):541-551.
Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT trial. The Lancet Diabetes & Endocrinology. 2019;7(5):344-355.
The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England Journal of Medicine. 2013;369(2):145-154.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). New England Journal of Medicine. 2015;373(22):2117-2128.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). New England Journal of Medicine. 2016;375(4):311-322.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). New England Journal of Medicine. 2019;380(24):2295-2306.
Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes (STENO-2). New England Journal of Medicine. 2003;348(5):383-393.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine. 2008;358(24):2545-2559.
American Diabetes Association. Introduction and methodology: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1-S4.

Live PubMed Searches

↑ Back to Table of Contents

Connections

↑ Back to Table of Contents